Ustekinumab for the Prevention of Acute Graft Versus Host Disease After Unrelated Donor Hematopoietic Cell Transplant
Status:
Recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ustekinumab works in preventing acute graft versus host
disease after unrelated donor hematopoietic cell transplant. Sometimes the transplanted cells
from a donor can attack the body's normal tissues (called graft-versus-host disease). Giving
ustekinumab after the transplant may help prevent acute graft versus host disease by
controlling the body's immune response.
Phase:
Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborator:
Food and Drug Administration (FDA)
Treatments:
Immunoglobulin G Immunoglobulins Interleukin-12 Ustekinumab